Recruiting Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation NCT07566585 Conditions AML - Acute Myeloid Leukemia, AML With Mutated NPM1, AML, Adult Recurrent, +11 more Locations Washington University at St Louis — St Louis, Missouri, United States View Trial Details
Recruiting Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT06001788 Conditions AML, AML With Mutated NPM1, Acute Leukemia, +14 more Locations Banner MD Anderson Cancer Center — Gilbert, Arizona, United States USC Norris Comprehensive Cancer Center — Los Angeles, California, United States UCLA Health - Bowyer Oncology Center — Los Angeles, California, United States UC Irvine Health Chao Family Comprehensive Cancer Center — Orange, California, United States View all 45 locations View more locations Show fewer locations Loading locations... View Trial Details
Recruiting A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML NCT05735184 Conditions AML With Mutated NPM1, Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, +19 more Locations Mayo Clinic - Phoenix — Phoenix, Arizona, United States Moores UC San Diego Cancer Center — La Jolla, California, United States USC / Norris Comprehensive Cancer Center — Los Angeles, California, United States UCLA - Bowyer Oncology Center — Los Angeles, California, United States View all 44 locations View more locations Show fewer locations Loading locations... View Trial Details
